New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

June 8, 2023Ryan ScottCaroline SeymourAcalabrutinib and zanubrutinib demonstrated similar investigator-assessed progression-free survival in patients with relapsed/refractory chronic lymphocytic leuke
World medicine November 21,2023
Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

June 8, 2023Ryan ScottCaroline SeymourAcalabrutinib and zanubrutinib demonstrated similar investigator-assessed progression-free survival in patients with relapsed/refractory chronic lymphocytic leuke
World medicine November 21,2023
Study finds substantial differences in cancer drug funding decisions across high-income countries

Study finds substantial differences in cancer drug funding decisions across high-income countries

Despite the use of similar assessment criteria when deciding whether new cancer drugs should receive funding, there are substantial differences in drug funding decisions, across comparable high-income
World medicine November 21,2023
Study finds substantial differences in cancer drug funding decisions across high-income countries

Study finds substantial differences in cancer drug funding decisions across high-income countries

Despite the use of similar assessment criteria when deciding whether new cancer drugs should receive funding, there are substantial differences in drug funding decisions, across comparable high-income
World medicine November 21,2023
New pan-cancer T cell atlas provides a deeper understanding of complex tumor microenvironment

New pan-cancer T cell atlas provides a deeper understanding of complex tumor microenvironment

A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today inNature Medicine, provides a deeper understanding of the vast diversity of T cell states as
World medicine November 21,2023
New pan-cancer T cell atlas provides a deeper understanding of complex tumor microenvironment

New pan-cancer T cell atlas provides a deeper understanding of complex tumor microenvironment

A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today inNature Medicine, provides a deeper understanding of the vast diversity of T cell states as
World medicine November 21,2023
Jaktinib Reduces Splenomegaly, Improves Symptom Burden in Ruxolitinib-intolerant Myelofibrosis

Jaktinib Reduces Splenomegaly, Improves Symptom Burden in Ruxolitinib-intolerant Myelofibrosis

June 13, 2023Ryan ScottThe novel JAK and AVCR1 inhibitor jaktinib demonstrated promising therapeutic activity in patients with myelofibrosis who were intolerant to or progressed on ruxolitinib.Jaktini
World medicine November 21,2023
Jaktinib Reduces Splenomegaly, Improves Symptom Burden in Ruxolitinib-intolerant Myelofibrosis

Jaktinib Reduces Splenomegaly, Improves Symptom Burden in Ruxolitinib-intolerant Myelofibrosis

June 13, 2023Ryan ScottThe novel JAK and AVCR1 inhibitor jaktinib demonstrated promising therapeutic activity in patients with myelofibrosis who were intolerant to or progressed on ruxolitinib.Jaktini
World medicine November 21,2023
Low-cost DNA test for HPV infections could improve access to cervical cancer screening

Low-cost DNA test for HPV infections could improve access to cervical cancer screening

Rice University bioengineers have demonstrated a low-cost, point-of-care DNA test for HPV infections that could make cervical cancer screening more accessible in low- and middle-income countries where
World medicine November 21,2023
Low-cost DNA test for HPV infections could improve access to cervical cancer screening

Low-cost DNA test for HPV infections could improve access to cervical cancer screening

Rice University bioengineers have demonstrated a low-cost, point-of-care DNA test for HPV infections that could make cervical cancer screening more accessible in low- and middle-income countries where
World medicine November 21,2023
Makeup of microbiome in a person's tumor varies depending on early or late-onset colorectal cancer

Makeup of microbiome in a person's tumor varies depending on early or late-onset colorectal cancer

Researchers at Georgetown University's Lombardi Comprehensive Cancer Center studied the microbiome of people with colorectal cancer and found the make-up of the bacteria, fungi and viruses in a pe
World medicine November 21,2023
Makeup of microbiome in a person's tumor varies depending on early or late-onset colorectal cancer

Makeup of microbiome in a person's tumor varies depending on early or late-onset colorectal cancer

Researchers at Georgetown University's Lombardi Comprehensive Cancer Center studied the microbiome of people with colorectal cancer and found the make-up of the bacteria, fungi and viruses in a pe
World medicine November 21,2023
FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer

FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer

June 6, 2023Kristi RosaThe FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients
World medicine November 21,2023
FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer

FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer

June 6, 2023Kristi RosaThe FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients
World medicine November 21,2023
Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-fr
World medicine November 21,2023
Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-fr
World medicine November 21,2023
BL-B01D1 Demonstrates Antitumor Activity in EGFR+ NSCLC and Other Solid Tumors

BL-B01D1 Demonstrates Antitumor Activity in EGFR+ NSCLC and Other Solid Tumors

June 7, 2023Ryan ScottThe first-in-class EGFR x HER3 bispecific antibody-drug conjugate BL-B01D1 generated antitumor activity and safety in patients with advanced solid tumors, particularly EGFR-mutat
World medicine November 21,2023
BL-B01D1 Demonstrates Antitumor Activity in EGFR+ NSCLC and Other Solid Tumors

BL-B01D1 Demonstrates Antitumor Activity in EGFR+ NSCLC and Other Solid Tumors

June 7, 2023Ryan ScottThe first-in-class EGFR x HER3 bispecific antibody-drug conjugate BL-B01D1 generated antitumor activity and safety in patients with advanced solid tumors, particularly EGFR-mutat
World medicine November 21,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com